Anti-Inflammatory Drugs — NSAIDs, Corticosteroids, and Gout

Correct Answer

C) Colchicine

Rationale

Colchicine is classified as a plant alkaloid, derived from the autumn crocus. Allopurinol and febuxostat are xanthine oxidase inhibitors used for urate-lowering therapy. Probenecid is a uricosuric agent.

Correct Answer

A) Allopurinol

Rationale

Allopurinol is classified as a xanthine oxidase inhibitor. Colchicine is a plant alkaloid used in acute gout. Pegloticase is a pegylated recombinant uricase. Probenecid is a uricosuric agent.

Correct Answer

D) Trimethoprim-sulfamethoxazole

Rationale

Trimethoprim-sulfamethoxazole is the preferred agent for Pneumocystis jirovecii pneumonia prophylaxis in immunosuppressed patients, including those receiving high-dose or prolonged corticosteroid therapy. It is the first-line choice because of its established efficacy, oral administration, and low cost. Dapsone, atovaquone, and inhaled pentamidine are all recognized alternative agents used when trimethoprim-sulfamethoxazole is not tolerated — most commonly due to sulfonamide allergy or significant adverse effects such as bone marrow suppression or renal toxicity. None of the alternatives has demonstrated superior efficacy to trimethoprim-sulfamethoxazole as first-line prophylaxis.

Correct Answer

B) Probenecid

Rationale

Probenecid is classified as a uricosuric agent. It reduces serum urate by blocking the proximal tubular transporters responsible for reabsorbing filtered urate, increasing renal urate excretion. Allopurinol and febuxostat are xanthine oxidase inhibitors that reduce uric acid production. Colchicine is a plant alkaloid used to treat and prevent acute gout attacks.

Correct Answer

C) Febuxostat

Rationale

Febuxostat is classified as a non-purine selective xanthine oxidase inhibitor. Unlike allopurinol, which is a structural analogue of the purine hypoxanthine, febuxostat has a non-purine structure and inhibits xanthine oxidase through a different binding mode. Probenecid is a uricosuric agent and colchicine is a plant alkaloid — neither inhibits xanthine oxidase.

Correct Answer

A) Pegloticase

Rationale

Pegloticase is classified as a pegylated recombinant uricase. It is a modified recombinant porcine uricase conjugated to polyethylene glycol, which converts uric acid to the more soluble metabolite allantoin. Febuxostat and allopurinol are xanthine oxidase inhibitors that reduce uric acid production. Probenecid is a uricosuric agent that increases renal urate excretion.

Correct Answer

D) Glucocorticoids suppress osteoblast activity, reducing bone formation, while simultaneously promoting osteoclast-mediated bone resorption through transcriptional mechanisms, producing net bone loss

Rationale

Glucocorticoid-induced osteoporosis results from a direct imbalance between bone formation and resorption driven by glucocorticoid receptor-mediated transcriptional changes. Glucocorticoids suppress osteoblast proliferation, differentiation, and function — reducing the synthesis of bone matrix proteins including type I collagen — and promote osteoblast and osteocyte apoptosis. Simultaneously, they prolong osteoclast survival and enhance osteoclast-mediated resorption. The greatest rate of bone loss occurs in the first three to six months of therapy, which is why bisphosphonate prophylaxis should be initiated early rather than after bone loss has occurred. Guidelines recommend bisphosphonate prophylaxis for patients receiving a prednisone-equivalent dose of 2.5 mg per day or higher for three months or longer, alongside calcium and vitamin D supplementation.

Correct Answer

B) Corticosteroids cause fat embolism and endothelial injury in the subchondral bone vasculature, producing ischemic necrosis of the bone at the femoral head

Rationale

Corticosteroid-induced avascular necrosis results from two converging vascular mechanisms in the subchondral bone. Glucocorticoids promote fat cell hypertrophy and fat embolism in the intraosseous vasculature, occluding small vessels supplying the subchondral bone. Glucocorticoids also cause endothelial injury in these vessels, further impairing blood flow. The resulting ischemia leads to osteocyte death and structural collapse, most commonly at the femoral head, humeral head, and femoral condyles. A clinically important feature is that avascular necrosis can follow even short high-dose corticosteroid courses — including pulse methylprednisolone — and may present months after treatment ends. Any patient who received high-dose corticosteroids and develops hip, knee, or shoulder pain requires magnetic resonance imaging evaluation, which detects avascular necrosis before plain radiographs become abnormal.

Correct Answer

A) Glucocorticoids act directly on glucocorticoid receptors in lens epithelial cells, altering their proliferation and differentiation and producing the characteristic posterior subcapsular opacity

Rationale

Posterior subcapsular cataracts are a direct glucocorticoid receptor-mediated effect on lens epithelial cells. Glucocorticoid receptors are expressed in lens epithelium, and receptor activation alters cell behavior — impairing normal epithelial-to-fiber cell differentiation and promoting abnormal cell accumulation in the posterior subcapsular region. The resulting opacity is characteristic: posterior subcapsular cataracts appear at the back of the lens just under the capsule and are optically distinct from age-related nuclear or cortical cataracts. The risk correlates with cumulative corticosteroid dose and duration of therapy and is largely irreversible. Increased intraocular pressure (option B) is a separate corticosteroid ophthalmic adverse effect involving trabecular meshwork dysfunction, and it is generally reversible on drug discontinuation — unlike posterior subcapsular cataracts.

Correct Answer

C) Phagocytosis of monosodium urate crystals by macrophages and neutrophils activates intracellular danger-sensing machinery that releases interleukin-1 beta, which recruits neutrophils and drives the acute inflammatory cascade

Rationale

When monosodium urate crystals are phagocytosed by synovial macrophages and neutrophils, the crystals are recognized as a danger signal by intracellular innate immune sensors. This activates a signaling cascade that results in the release of interleukin-1 beta — the central cytokine driving the acute gout attack. Interleukin-1 beta acts on synovial endothelium and surrounding tissues to recruit neutrophils into the joint space. Neutrophil influx amplifies the response: newly recruited neutrophils phagocytose additional crystals, release more interleukin-1 beta, and sustain the self-amplifying inflammatory loop that produces the characteristic rapid escalation of gout pain and swelling. This central role of interleukin-1 beta explains the mechanism of biologic agents that specifically block interleukin-1 signaling (such as anakinra and canakinumab) and is relevant to understanding why colchicine, which impairs neutrophil chemotaxis and crystal phagocytosis, interrupts this cascade early. Interleukin-1 beta is not preformed in crystals (option A), does not activate complement to lyse chondrocytes (option B), and does not act through immunoglobulin E on mast cells (option D).

Correct Answer

D) Colchicine binds tubulin and inhibits microtubule polymerization, impairing neutrophil chemotaxis, phagocytosis, degranulation, and NLRP3 inflammasome assembly

Rationale

Colchicine's mechanism is distinct from all other gout therapies. It does not lower serum urate, block cytokine receptors, or inhibit cyclooxygenase. Instead, it binds tubulin — the structural protein of microtubules — and prevents microtubule polymerization. Intact microtubules are required for neutrophil polarization and chemotaxis toward the inflamed joint, phagosome formation and crystal engulfment, granule secretion, and the microtubule-dependent assembly of the NLRP3 inflammasome itself. By disrupting all of these processes, colchicine attenuates the acute gout attack at multiple points in the inflammatory cascade. Low-dose colchicine (1.2 mg at onset followed by 0.6 mg one hour later) is as effective as historical high-dose regimens with substantially less gastrointestinal toxicity, and it must be initiated within 36 hours of attack onset for maximal benefit.

Correct Answer

B) Allopurinol is metabolized by xanthine oxidase to its primary active species, oxypurinol, which is renally cleared; in chronic kidney disease oxypurinol accumulates, increasing the risk of the allopurinol hypersensitivity syndrome

Rationale

Allopurinol is a structural analogue of hypoxanthine that inhibits xanthine oxidase, reducing the conversion of hypoxanthine and xanthine to uric acid. Allopurinol itself is rapidly metabolized by xanthine oxidase to oxypurinol — the species responsible for most of the sustained xanthine oxidase inhibition. Oxypurinol has a long half-life and is excreted renally. In patients with chronic kidney disease, oxypurinol clearance is reduced and plasma concentrations rise. Elevated oxypurinol concentrations are the principal pharmacokinetic driver of the allopurinol hypersensitivity syndrome — a potentially life-threatening reaction characterized by fever, rash (ranging from maculopapular to Stevens-Johnson syndrome), hepatitis, and renal failure. Starting allopurinol at a low dose (50 to 100 mg per day) and titrating slowly reduces this risk regardless of renal function.

Correct Answer

A) Colchicine is a substrate of both cytochrome P450 3A4 and P-glycoprotein; potent inhibitors of either pathway reduce colchicine clearance, raising its plasma concentration to levels that cause myopathy, neuromuscular toxicity, and cytopenias

Rationale

Colchicine has a narrow therapeutic index and depends on two major elimination pathways: hepatic metabolism by cytochrome P450 3A4 and efflux transport by P-glycoprotein in the intestinal wall, liver, and kidney. Potent inhibitors of cytochrome P450 3A4 — including clarithromycin, ritonavir, and azole antifungals — reduce colchicine hepatic clearance. Potent P-glycoprotein inhibitors — including cyclosporine — reduce intestinal efflux and renal secretion of colchicine. When either or both pathways are inhibited, colchicine plasma concentrations rise to levels that produce toxicity: myopathy, neuromuscular toxicity, and cytopenias from bone marrow suppression. Fatal colchicine toxicity has been reported with these combinations. When combination cannot be avoided, colchicine dose must be reduced and the duration kept as brief as possible.

Correct Answer

C) Rapid reduction in serum urate destabilizes existing monosodium urate crystal deposits in tissue, causing crystals to shed into the joint space where they activate NLRP3 inflammasome-mediated inflammation

Rationale

Monosodium urate crystals in tophaceous deposits and joint tissues exist in equilibrium with dissolved serum urate. When urate-lowering therapy rapidly lowers serum urate concentrations, this equilibrium is disturbed — existing crystal deposits begin to dissolve and shed monosodium urate crystals into the joint space. These newly mobilized crystals are phagocytosed by synovial macrophages and neutrophils, activating the NLRP3 inflammasome and triggering acute gout attacks. This crystal shedding phenomenon typically peaks in the first three to six months of urate-lowering therapy, before existing crystal deposits have fully dissolved. The standard management is co-prescribing prophylactic colchicine for at least the first three to six months of urate-lowering therapy. Patients already established on urate-lowering therapy who experience a flare should continue their therapy without interruption — stopping would cause serum urate to rise again, worsening crystal instability.

Correct Answer

B) Colchicine binds tubulin and disrupts microtubule polymerization, impairing neutrophil chemotaxis to the inflamed joint and blocking NLRP3 inflammasome assembly, attenuating the inflammatory cascade

Rationale

Colchicine's mechanism in acute gout is purely anti-inflammatory — it does not affect serum urate levels, crystal formation, cytokine receptors, or cyclooxygenase. It binds free tubulin and prevents the assembly of microtubules, which are required for neutrophil polarization, chemotaxis toward the inflamed joint, crystal phagocytosis, granule secretion, and NLRP3 inflammasome assembly. By disrupting these microtubule-dependent processes, colchicine reduces the neutrophil influx that amplifies the acute gout attack and limits further NLRP3-driven interleukin-1 beta production. Efficacy is time-dependent: colchicine is most effective when started within 36 hours of attack onset, and its benefit diminishes with later initiation. The low-dose regimen (1.2 mg followed by 0.6 mg one hour later) is as effective as higher doses with substantially less gastrointestinal toxicity.

Correct Answer

D) Ritonavir inhibits both cytochrome P450 3A4 and P-glycoprotein, reducing colchicine clearance and raising its plasma concentration to levels that can cause myopathy, cytopenias, and potentially fatal toxicity

Rationale

Colchicine has a narrow therapeutic index. Its two principal elimination pathways — hepatic metabolism by cytochrome P450 3A4 and efflux by P-glycoprotein — are both inhibited by ritonavir. When ritonavir is present, colchicine clearance is reduced and plasma concentrations rise to potentially toxic levels. The resulting toxicity includes proximal myopathy, neuromuscular dysfunction, and bone marrow suppression causing cytopenias. Fatal outcomes have been reported with this combination. Standard colchicine doses that are well tolerated without ritonavir can produce life-threatening toxicity when ritonavir is co-administered. If colchicine must be used in a patient on ritonavir, the dose must be reduced and treatment limited to the shortest possible duration.

Correct Answer

A) Allopurinol is metabolized to oxypurinol, which accumulates in patients with reduced renal clearance; elevated oxypurinol concentrations are the principal pharmacokinetic driver of the allopurinol hypersensitivity syndrome, and starting at a dose disproportionate to renal function increases this risk

Rationale

The allopurinol hypersensitivity syndrome is a potentially life-threatening reaction ranging from a maculopapular rash to Stevens-Johnson syndrome and toxic epidermal necrolysis, accompanied by fever, hepatitis, eosinophilia, and renal failure. The primary pharmacokinetic risk factor is oxypurinol accumulation. Allopurinol is rapidly metabolized to oxypurinol by xanthine oxidase; oxypurinol is the primary pharmacologically active species and is renally excreted. In patients with chronic kidney disease — as in this patient with an estimated glomerular filtration rate of 42 mL per minute — oxypurinol clearance is reduced, and starting allopurinol at 300 mg daily may result in oxypurinol concentrations that drive the hypersensitivity reaction. Guidelines recommend starting allopurinol at 50 to 100 mg per day and titrating slowly in all patients, with particular caution in those with renal impairment. The HLA-B*5801 allele is also a genetic risk factor, more prevalent in Han Chinese, Korean, and Thai populations.

Correct Answer

C) Approximately 40 to 50 percent of patients develop neutralizing antibodies against pegloticase that abolish its uricase activity; loss of serum urate response signals antibody formation, and continuing infusions in an antibody-positive patient carries a high risk of anaphylaxis

Rationale

Pegloticase converts uric acid to allantoin and maintains very low serum urate in responding patients. However, because pegloticase is a large porcine protein, approximately 40 to 50% of patients develop anti-drug antibodies that neutralize its enzymatic activity. The first detectable signal of antibody formation is a rise in serum urate above 6 mg/dL. The critical safety implication is that patients who have developed anti-drug antibodies face a high risk of anaphylaxis and serious infusion reactions if they receive additional infusions. Current guidelines require that pegloticase be discontinued when serum urate rises above 6 mg/dL, before the next scheduled infusion. Monitoring serum urate before each infusion is therefore a mandatory safety protocol. Co-administration of methotrexate reduces anti-drug antibody formation and is now endorsed in guidelines as a strategy to improve durable urate-lowering response.